111 related articles for article (PubMed ID: 23334725)
21. Clinical values for abnormal ¹⁸F-FDG uptake in the head and neck region of patients with head and neck squamous cell carcinoma.
Lee HS; Kim JS; Roh JL; Choi SH; Nam SY; Kim SY
Eur J Radiol; 2014 Aug; 83(8):1455-60. PubMed ID: 24929443
[TBL] [Abstract][Full Text] [Related]
22. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Roos JC; de Bree R; Wilhelm AJ; Kummer JA; Hanft G; Heider KH; Stehle G; Snow GB; van Dongen GA
Cancer Immunol Immunother; 2003 Sep; 52(9):576-82. PubMed ID: 14627130
[TBL] [Abstract][Full Text] [Related]
23. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
24. Whole-body distribution and radiation dosimetry of (68)Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging.
Kim JH; Lee JS; Kang KW; Lee HY; Han SW; Kim TY; Lee YS; Jeong JM; Lee DS
Cancer Biother Radiopharm; 2012 Feb; 27(1):65-71. PubMed ID: 22149685
[TBL] [Abstract][Full Text] [Related]
25. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
Schinagl DA; Vogel WV; Hoffmann AL; van Dalen JA; Oyen WJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1282-9. PubMed ID: 17967318
[TBL] [Abstract][Full Text] [Related]
26. Validation for performing ¹¹C-methionine and ¹⁸F-FDG-PET studies on the same day.
Mitsumoto T; Kubota K; Sato T; Morooka M; Minamimoto R; Shimbo T; Muramatsu Y; Sasaki T; Ito K; Fukushi M
Nucl Med Commun; 2012 Mar; 33(3):297-304. PubMed ID: 22107999
[TBL] [Abstract][Full Text] [Related]
27. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
[TBL] [Abstract][Full Text] [Related]
28. Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism.
Mahy P; Geets X; Lonneux M; Levêque P; Christian N; De Bast M; Gillart J; Labar D; Lee J; Grégoire V
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1282-9. PubMed ID: 18317752
[TBL] [Abstract][Full Text] [Related]
29. In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts.
Xie H; Wang ZJ; Bao A; Goins B; Phillips WT
Int J Pharm; 2010 Aug; 395(1-2):324-30. PubMed ID: 20540999
[TBL] [Abstract][Full Text] [Related]
30. Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.
Terry SY; Abiraj K; Frielink C; van Dijk LK; Bussink J; Oyen WJ; Boerman OC
J Nucl Med; 2014 Feb; 55(2):281-6. PubMed ID: 24408894
[TBL] [Abstract][Full Text] [Related]
31. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.
Lehtiö K; Oikonen V; Nyman S; Grönroos T; Roivainen A; Eskola O; Minn H
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):101-8. PubMed ID: 12483416
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
[TBL] [Abstract][Full Text] [Related]
33. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck.
Schmid DT; Stoeckli SJ; Bandhauer F; Huguenin P; Schmid S; von Schulthess GK; Goerres GW
Laryngoscope; 2003 May; 113(5):888-91. PubMed ID: 12792328
[TBL] [Abstract][Full Text] [Related]
34. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
[TBL] [Abstract][Full Text] [Related]
35. Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma.
Jeong HS; Baek CH; Son YI; Ki Chung M; Kyung Lee D; Young Choi J; Kim BT; Kim HJ
Head Neck; 2007 Mar; 29(3):203-10. PubMed ID: 17111430
[TBL] [Abstract][Full Text] [Related]
36. New tracers beyond FDG in head and neck oncology.
Gornik G; Weber W
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):529-40. PubMed ID: 22019710
[TBL] [Abstract][Full Text] [Related]
37. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer.
Shintani SA; Foote RL; Lowe VJ; Brown PD; Garces YI; Kasperbauer JL
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):322-9. PubMed ID: 17889447
[TBL] [Abstract][Full Text] [Related]
38. Head and neck cancer: effect of food ingestion on uptake of C-11 methionine.
Lindholm P; Leskinen-Kallio S; Kirvelä O; Någren K; Lehikoinen P; Pulkki K; Peltola O; Ruotsalainen U; Teräs M; Joensuu H
Radiology; 1994 Mar; 190(3):863-7. PubMed ID: 8115641
[TBL] [Abstract][Full Text] [Related]
39. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
[TBL] [Abstract][Full Text] [Related]
40. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
McCollum AD; Burrell SC; Haddad RI; Norris CM; Tishler RB; Case MA; Posner MR; Van den Abbeele AD
Head Neck; 2004 Oct; 26(10):890-6. PubMed ID: 15390197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
